# Labcorp Holdings Inc.: overview

LH · NYSE · CIK 920148 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lh.md) · [Financials](/companies/lh/financials.md) · [Filings](/companies/lh/filings.md) · [Insiders](/companies/lh/insiders.md)

Latest reported revenue: [$3.73bn](/filings/0000920148-26-000175.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0000920148-26-000175).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,282](/filings/0000920148-25-000096.md) | [3,329 d](/filings/0000920148-26-000111.md) | [3,345](/filings/0000920148-26-000139.md) | [3,527](/filings/0000920148-26-000175.md) | [3,564](/filings/0000920148-25-000096.md) | [3,516 d](/filings/0000920148-26-000111.md) | [3,538](/filings/0000920148-26-000139.md) | [3,731](/filings/0000920148-26-000175.md) |
| Gross margin | % | [27.6%](/filings/0000920148-25-000096.md) | [26.9% d](/filings/0000920148-26-000111.md) | [28.3%](/filings/0000920148-26-000139.md) | [29.7%](/filings/0000920148-26-000175.md) | [28.8%](/filings/0000920148-25-000096.md) | [28.2% d](/filings/0000920148-26-000111.md) | [28.7%](/filings/0000920148-26-000139.md) | [29.8%](/filings/0000920148-26-000175.md) |
| Operating margin | % | [7.7%](/filings/0000920148-25-000096.md) | [6.5% d](/filings/0000920148-26-000111.md) | [9.7%](/filings/0000920148-26-000139.md) | [11.2%](/filings/0000920148-26-000175.md) | [11.1%](/filings/0000920148-25-000096.md) | [7.6% d](/filings/0000920148-26-000111.md) | [10.8%](/filings/0000920148-26-000139.md) | [12.1%](/filings/0000920148-26-000175.md) |
| Net margin | % | [5.2%](/filings/0000920148-25-000096.md) | [4.3% d](/filings/0000920148-26-000111.md) | [6.4%](/filings/0000920148-26-000175.md) | [6.7%](/filings/0000920148-26-000175.md) | [7.3%](/filings/0000920148-25-000096.md) | [4.7% d](/filings/0000920148-26-000111.md) | [7.9%](/filings/0000920148-26-000175.md) | [8.0%](/filings/0000920148-26-000175.md) |
| Diluted EPS | $ per share | [2.00](/filings/0000920148-25-000096.md) | not reported | [2.52](/filings/0000920148-26-000139.md) | [2.84](/filings/0000920148-26-000175.md) | [3.12](/filings/0000920148-25-000096.md) | not reported | [3.35](/filings/0000920148-26-000139.md) | [3.64](/filings/0000920148-26-000175.md) |
| Free cash flow | $m | [162 d](/filings/0000920148-25-000096.md) | [665 d](/filings/0000920148-26-000111.md) | [(108)](/filings/0000920148-26-000139.md) | [543 d](/filings/0000920148-26-000175.md) | [281 d](/filings/0000920148-25-000096.md) | [490 d](/filings/0000920148-26-000111.md) | [70.5](/filings/0000920148-26-000139.md) | [314 d](/filings/0000920148-26-000175.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [13.1](/filings/0000920148-24-000014.md) | [11.9](/filings/0000920148-25-000032.md) | [12.2](/filings/0000920148-26-000111.md) | [13.0](/filings/0000920148-26-000111.md) | [14.0](/filings/0000920148-26-000111.md) |
| Gross margin | % | [38.0%](/filings/0000920148-24-000014.md) | [31.3%](/filings/0000920148-25-000032.md) | [27.7%](/filings/0000920148-26-000111.md) | [27.9%](/filings/0000920148-26-000111.md) | [28.8%](/filings/0000920148-26-000111.md) |
| Operating margin | % | [23.2%](/filings/0000920148-24-000014.md) | [12.1%](/filings/0000920148-25-000032.md) | [6.0%](/filings/0000920148-26-000111.md) | [8.4%](/filings/0000920148-26-000111.md) | [9.9%](/filings/0000920148-26-000111.md) |
| Net margin | % | [18.1%](/filings/0000920148-24-000014.md) | [10.8%](/filings/0000920148-25-000032.md) | [3.4%](/filings/0000920148-26-000111.md) | [5.7%](/filings/0000920148-26-000111.md) | [6.3%](/filings/0000920148-26-000111.md) |
| Diluted EPS | $ per share | [24.39](/filings/0000920148-24-000014.md) | [13.97](/filings/0000920148-25-000032.md) | [4.77](/filings/0000920148-26-000111.md) | [8.84](/filings/0000920148-26-000111.md) | [10.46](/filings/0000920148-26-000111.md) |
| Free cash flow | $bn | [2.7](/filings/0000920148-24-000014.md) | [1.5](/filings/0000920148-25-000032.md) | [0.9](/filings/0000920148-26-000111.md) | [1.1](/filings/0000920148-26-000111.md) | [1.2](/filings/0000920148-26-000111.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lh/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.84bn | 6,574,261 |  | Added +129,405 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.50bn | 5,362,254 |  | Reduced −13,866 |
| [VICTORY CAPITAL MANAGEMENT INC](/funds/1040188.md) | 2026-06-30 | $1.35bn | 4,837,573 |  | Added +210,447 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.09bn | 3,907,656 |  | Added +44,485 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.03bn | 3,678,798 |  | Reduced −1,863 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $854.2m | 3,051,690 |  | Added +682,894 |
| [Allspring Global Investments Holdings, LLC](/funds/1890906.md) | 2026-06-30 | $635.0m | 2,236,957 |  | Added +10,511 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $610.4m | 2,188,890 |  | Added +2,948 |
| [Select Equity Group, L.P.](/funds/1592643.md) | 2026-06-30 | $554.9m | 1,981,948 |  | Reduced −192,837 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $533.4m | 1,904,870 |  | Added +616,459 |

## Recent filings

[All 2,329 filings](/companies/lh/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 16:11 ET | [10-Q](/filings/0000920148-26-000222.md) | Quarterly report, period 2026-09-30 | 0000920148-26-000222 |
| 2026-10-28 | 06:57 ET | [8-K](/filings/0000920148-26-000213.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000920148-26-000213 |
| 2026-10-21 | 06:51 ET | [8-K](/filings/0000920148-26-000210.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000920148-26-000210 |
| 2026-09-30 | 08:32 ET | [8-K](/filings/0000920148-26-000207.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000920148-26-000207 |
| 2026-09-22 | 16:43 ET | [8-K](/filings/0000920148-26-000205.md) | 7.01 Regulation FD disclosure | 0000920148-26-000205 |
| 2026-09-10 | 16:47 ET | [8-K](/filings/0000920148-26-000201.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000920148-26-000201 |
| 2026-08-28 | 08:33 ET | [8-K](/filings/0000920148-26-000189.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000920148-26-000189 |
| 2026-08-17 | 08:03 ET | [8-K](/filings/0000920148-26-000185.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000920148-26-000185 |
| 2026-08-14 | 08:55 ET | [8-K](/filings/0000920148-26-000182.md) | 5.02 Departure or appointment of officers or directors | 0000920148-26-000182 |
| 2026-08-05 | 16:15 ET | [10-Q](/filings/0000920148-26-000175.md) | Quarterly report, period 2026-06-30 | 0000920148-26-000175 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000920148-26-000111.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0b75b148-ef49-4d09-ac75-03d108d6d32e)

## About the filer

- CIK: 920148
- Tickers: LH
- Exchange: NYSE
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:19 ET. No prices; not investment advice.